ArticleFrontiers in medicine2026
Precision management of severe coronary artery calcification with concomitant left ventricular outflow tract obstruction: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe coronary artery calcification (CAC) with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction (LVOTO) present complex diagnostic and therapeutic challenges. Case presentation: A 72-year-old man with exertional chest pain and dyspnea exhibited multivessel CAC (total score; 1,696), asymmetric septal hypertrophy, and dynamic LVOTO. Percutaneous coronary intervention (PCI) was performed on the right coronary artery (RCA) and left circumflex artery (LCX) guided by quantitative flow ratio (QFR) and intravascular ultrasound (IVUS). Left anterior descending artery (LAD) lesions showed preserved function but microvascular dysfunction; no intervention was performed. Cardiac magnetic resonance imaging confirmed HCM with segmental fibrosis and LVOTO. Intervention and outcome: Post-PCI, dual antiplatelet therapy was administered for 6 months, followed by aspirin monotherapy and oral mavacam (2.5 mg daily. After 4 months, the LVOT gradient decreased from 51 mmHg to 9-12 mmHg, with symptom resolution. Conclusion: Multimodal management combining coronary physiology, intravascular imaging, and targeted pharmacotherapy effectively relieved myocardial ischemia and LVOTO, thereby providing a reference for complex cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.